Drugs / ALX-009
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02598999 | Nov 2015 → Dec 2021 | bronchiectasis, cystic fibrosis | Alaxia SAS | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALX-009 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02598999 ↗ |
| Known as | Meveol | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297691 ↗ |
| Route | Inhaled | “Solution for inhalation administered through nebulization” NCT02598999 ↗ |